These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27349376)

  • 1. NEK2 regulates stem-like properties and predicts poor prognosis in hepatocellular carcinoma.
    Lin S; Zhou S; Jiang S; Liu X; Wang Y; Zheng X; Zhou H; Li X; Cai X
    Oncol Rep; 2016 Aug; 36(2):853-62. PubMed ID: 27349376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation.
    Wen S; Liu Y; Yang M; Yang K; Huang J; Feng D
    Oncol Rep; 2016 Oct; 36(4):2193-9. PubMed ID: 27509921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
    Deng L; Sun J; Chen X; Liu L; Wu D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NEK2 serves as a prognostic biomarker for hepatocellular carcinoma.
    Li G; Zhong Y; Shen Q; Zhou Y; Deng X; Li C; Chen J; Zhou Y; He M
    Int J Oncol; 2017 Feb; 50(2):405-413. PubMed ID: 28101574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of β-catenin signaling.
    Lei ZJ; Wang J; Xiao HL; Guo Y; Wang T; Li Q; Liu L; Luo X; Fan LL; Lin L; Mao CY; Wang SN; Wei YL; Lan CH; Jiang J; Yang XJ; Liu PD; Chen DF; Wang B
    Oncogene; 2015 Jun; 34(24):3188-98. PubMed ID: 25893304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low expression of NEK2 is associated with hepatocellular carcinoma progression and poor prognosis.
    Fu L; Liu S; Wang H; Ma Y; Li L; He X; Mou X; Tong X; Hu Z; Ru G
    Cancer Biomark; 2017 Jul; 20(1):101-106. PubMed ID: 28759960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic cancer stem cell marker granulin-epithelin precursor and β-catenin expression associate with recurrence in hepatocellular carcinoma.
    Cheung PF; Cheung TT; Yip CW; Ng LW; Fung SW; Lo CM; Fan ST; Cheung ST
    Oncotarget; 2016 Apr; 7(16):21644-57. PubMed ID: 26942873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High NEK2 Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy.
    Wubetu GY; Morine Y; Teraoku H; Yoshikawa M; Ishikawa D; Yamada S; Ikemoto T; Saito YU; Imura S; Shimada M
    Anticancer Res; 2016 Feb; 36(2):757-62. PubMed ID: 26851035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-452 promotes stem-like cells of hepatocellular carcinoma by inhibiting Sox7 involving Wnt/β-catenin signaling pathway.
    Zheng Z; Liu J; Yang Z; Wu L; Xie H; Jiang C; Lin B; Chen T; Xing C; Liu Z; Song P; Yin S; Zheng S; Zhou L
    Oncotarget; 2016 May; 7(19):28000-12. PubMed ID: 27058905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
    Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
    EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulated FSTL5 promotes cell proliferation and survival by affecting Wnt/β-catenin signaling in hepatocellular carcinoma.
    Zhang D; Ma X; Sun W; Cui P; Lu Z
    Int J Clin Exp Pathol; 2015; 8(3):3386-94. PubMed ID: 26045876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of NEK2 and its interaction with NDC80 and CEP250 in hepatocellular carcinoma.
    Zeng L; Fan X; Wang X; Deng H; Zhang X; Zhang K; He S; Li N; Han Q; Liu Z
    BMC Med Genomics; 2020 Oct; 13(1):158. PubMed ID: 33109182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression.
    Wu SM; Lin SL; Lee KY; Chuang HC; Feng PH; Cheng WL; Liao CJ; Chi HC; Lin YH; Tsai CY; Chen WJ; Yeh CT; Lin KH
    Int J Cancer; 2017 Apr; 140(7):1581-1596. PubMed ID: 27925179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling.
    Shen YN; He HG; Shi Y; Cao J; Yuan JY; Wang ZC; Shi CF; Zhu N; Wei YP; Liu F; Huang JL; Yang GS; Lu JH
    Mol Carcinog; 2017 Feb; 56(2):751-760. PubMed ID: 27478926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch3 functions as a regulator of cell self-renewal by interacting with the β-catenin pathway in hepatocellular carcinoma.
    Zhang Q; Lu C; Fang T; Wang Y; Hu W; Qiao J; Liu B; Liu J; Chen N; Li M; Zhu R
    Oncotarget; 2015 Feb; 6(6):3669-79. PubMed ID: 25668819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Significance of NEK2 in Hepatocellular Carcinoma: Evidence from a Meta-Analysis and Retrospective Cohort Study.
    Cheng Y; Chen X; Ye L; Zhang Y; Liang J; Liu W; Zhou B; Zheng S; Huang Y; Chen G; Deng Y; Zhang Q; Yang Y
    Cell Physiol Biochem; 2018; 51(6):2746-2759. PubMed ID: 30562736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma.
    Tanaka K; Tomita H; Hisamatsu K; Nakashima T; Hatano Y; Sasaki Y; Osada S; Tanaka T; Miyazaki T; Yoshida K; Hara A
    Oncotarget; 2015 Sep; 6(28):24722-32. PubMed ID: 26160842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/β-catenin pathway.
    Chao HM; Huang HX; Chang PH; Tseng KC; Miyajima A; Chern E
    Oncotarget; 2017 Jan; 8(2):2604-2616. PubMed ID: 27911878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
    Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
    Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NEK2 promotes hepatocellular carcinoma migration and invasion through modulation of the epithelial-mesenchymal transition.
    Zhang Y; Wang W; Wang Y; Huang X; Zhang Z; Chen B; Xie W; Li S; Shen S; Peng B
    Oncol Rep; 2018 Mar; 39(3):1023-1033. PubMed ID: 29399700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.